Results 11 to 20 of about 14,970 (304)

Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation [PDF]

Molecules, 2019
In thrombolytic therapy, plasminogen activators (PAs) are still the only group of drug approved to induce thrombolysis, and therefore, critical for treatment of arterial thromboembolism, such as stroke, in the acute phase.
Yunn-Hwa Ma, Jyh-Ping Chen, Tony Wu
exaly   +4 more sources

Plasminogen Activators in Neurovascular and Neurodegenerative Disorders. [PDF]

Int J Mol Sci, 2021
The neurovascular unit (NVU) is a dynamic structure assembled by endothelial cells surrounded by a basement membrane, pericytes, astrocytes, microglia and neurons.
Yepes M, Woo Y, Martin-Jimenez C.
europepmc   +2 more sources

Premature delivery impacts the concentration of plasminogen activators and a plasminogen activator inhibitor and the plasmin activity in human milk [PDF]

Frontiers in Pediatrics, 2022
Background and aimsPlasmin in human milk partially hydrolyzes milk proteins within the mammary gland and may enhance the hydrolysis of milk proteins within the infant’s stomach. This study examined the effects of extremely preterm (EP)-, very preterm (VP)
Veronique Demers-Mathieu, Mark A. Underwood, David C. Dallas   +2 more
doaj   +2 more sources

Causal association of plasminogen activators and their inhibitors with Alzheimer's disease: a Mendelian randomization study. [PDF]

Arch Med Sci
Introduction Alzheimer’s disease (AD) is the most common cause of dementia and contributes to a huge burden of disease worldwide. Observational studies have found that tissue plasminogen activator (t-PA) inhibits the development of AD, but little is ...
Guo X, Gao F, Pan B, Gao F, Zhang J, Wang S, Niu Q.   +6 more
europepmc   +2 more sources

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1 [PDF]

Data in Brief, 2016
Thrombosis is a leading cause of death worldwide [1]. Recombinant tissue-type plasminogen activator (tPA) is the FDA-approved thrombolytic drug for ischemic strokes, myocardial infarction and pulmonary embolism.
Lihu Gong, Min Liu, Tu Zeng, Xiaoli Shi, Cai Yuan, Peter A. Andreasen, Mingdong Huang   +6 more
doaj   +2 more sources

Adaption of the plasmin generation assay to enhance sensitivity to plasminogen activator inhibitor-1 and establishment of sex-specific reference values in human plasma [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Pharmacologic modifiers of fibrinolysis are used to modulate bleeding and thrombosis. Characterization of a sensitive plasmin generation (PG) assay to identify abnormal fibrinolytic states and monitor antifibrinolytic medication may improve ...
Ilaria De Simone, Kieran Pocknell, Samia Tufaha, Joke Konings, Mark Roest, Alisa S. Wolberg, Claire S. Whyte, Nicola J. Mutch, Bas de Laat, Dana Huskens   +9 more
doaj   +2 more sources

Support vector machine (SVM) based multiclass prediction with basic statistical analysis of plasminogen activators. [PDF]

BMC Res Notes, 2014
Plasminogen (Pg), the precursor of the proteolytic and fibrinolytic enzyme of blood, is converted to the active enzyme plasmin (Pm) by different plasminogen activators (tissue plasminogen activators and urokinase), including the bacterial activators ...
Muthukrishnan S, Puri M, Lefevre C.
europepmc   +3 more sources

Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis

Clinical and Experimental Immunology, 2008
Summary Tissue-type plasminogen activators (tPA) and urokinase-type plasminogen activators (uPA) are involved in liver repair. We examined the potential immunomodulatory actions of uPA, tPA and uPA-receptor (uPAR) in carbon-tetrachloride ...
O Pappo, Scott L Friedman, Rifaat Safadi   +2 more
exaly   +2 more sources

Increased Bone Formation in Mice Lacking Plasminogen Activators

Journal of Bone and Mineral Research, 2003
Plasminogen activators tPA and uPA are involved in tissue remodeling, but their role in bone growth is undefined. Mice lacking tPA and uPA show increased bone formation and bone mass.
E Van Herck, Roger Bouillon, Geert Carmeliet   +2 more
exaly   +2 more sources

Novel Roles for Urokinase- and Tissue-Type Plasminogen Activators in the Pathogenesis of Mood Disorders. [PDF]

Int J Mol Sci
This narrative review explores the intricate relationship between the plasminogen activator system (PAS), comprising urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), and a range of neuropsychiatric disorders ...
Bahi A, Steele S.
europepmc   +2 more sources